Efficacy of 125I seed implantation combined with PD-1 monoclonal antibody in treatment of stage IV non-small cell lung cancer
10.3760/cma.j.cn113030-20230809-00044
- VernacularTitle:125I粒子植入联合PD-1单抗治疗Ⅳ期非小细胞肺癌的疗效
- Author:
Zhe ZHANG
1
;
Peng DU
;
Fuqiang JIANG
;
Peng XIE
;
Jiacheng ZHANG
Author Information
1. 解放军总医院第六医学中心放射诊断科，北京 100080
- Keywords:
Carcinoma, non-small-cell lung;
125I seed implantation;
Anti-programmed death-1 monoclonal antibody;
Chemotherapy
- From:
Chinese Journal of Radiation Oncology
2024;33(6):518-523
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the efficacy of 125I seed implantation combined with programmed cell death 1 (PD-1) monoclonal antibody in the treatment of patients with stage Ⅳ non-small cell lung cancer. Methods:A retrospective analysis was performed on 106 patients with stage Ⅳ non-small cell lung cancer treated in Department of Radiology of the Sixth Medical Center of PLA General Hospital from February 2017 to January 2020. All patients were divided into the combination group, radiotherapy group and immunotherapy group according to treatment methods. Besides conventional chemotherapy in all three groups, 125I seed implantation combined with PD-1 monoclonal antibody therapy was given in the combination group, 125I seed implantation therapy was delivered in the radiotherapy, and PD-1 monoclonal antibody therapy was supplemented in the immunotherapy group, respectively. Differences in the general data, maximum tumor diameter, efficacy, progression-free survival (PFS) and safety among the three groups were analyzed. One-way ANOVA was used for comparison between groups, paired sample t-test was used for comparison before and after treatment. Kaplan-Meier method was used to calculate the survival rate, and log-rank test was used to compare the survival curve. Results:After treatment, the maximum tumor diameter in the three groups was decreased, and the data in the combination group was smaller than those in the radiotherapy and immunotherapy groups ( F=4.67, P=0.011). The objective response rate (ORR), disease control rate (DCR) and PFS rate in the combination group were higher than those in the radiotherapy and immunotherapy groups ( χ2=18.93, P<0.001; χ2=11.11, P=0.004; χ2=6.67, P=0.036), and the ORR in the immunoradiotherapy group was higher than that in the radiotherapy group ( χ2=4.23, P=0.040). There was no significant difference in the occurrence of adverse reactions among the three groups ( χ2=1.60, P=0.449). Conclusion:125I seed implantation combined with PD-1 monoclonal antibody may yield high efficacy in patients with stage Ⅳ non-small cell lung cancer, which can alleviate clinical symptoms and improve long-term survival rate with good safety.
